Dr. Peter Grimm, D.O.

As Director of Clinical Research, Dr. Grimm was instrumental in the establishment of the Seattle Prostate Institute and the shaping of its clinical, educational, and research activities. Since his involvement in establishing the first transperineal prostate implantation program in the United States, Dr. Grimm has devoted considerable effort to bringing about improvements in both the technical aspects of the implant procedure and the standards of practice among physicians and other clinical staff providing implantation services.
On the technical side, Dr. Grimm's creative endeavors have lead to continuous improvements in the equipment and supplies widely used in prostate implantation. He was the principal developer of the I-125 Rapid Strand designed to eliminate movement of seeds inside the prostate and he has been granted patents for an advanced design of the needles used in implant procedures, a pubic arch detection tool and improved spacer to link seeds ( Seed Link). As for raising practice standards, Dr. Grimm organized SPI's successful and highly regarded clinical education program and makes himself available to physicians newly trained in prostate brachytherapy as an OR proctor and consultant. He also created and is CEO of ProQura, an organization that provides quality assurance, radiation physics and dosimetry planning services to brachytherapy centers around the world.
As with the entire SPI medical team, Dr. Grimm has written on various aspects of prostate implantation for professional journals and other medical publications. His current research interests include quality assurance standards, seed migration, the maintenance of potency following implantation, and the minimization of prostate movement during the implant procedure.

Dr. Grimm received his medical education at the Chicago College of Osteopathic Medicine and his graduate training in radiation oncologist at UCLA.